US0327241065 - Common Stock
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...
The company's immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor.
The company is working on treatments for immunological diseases, including eczema and rheumatoid arthritis.
Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi
Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi...
ANAB stock results show that AnaptysBio missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AnaptysBio (NASDAQ:ANAB) just reported results for the second quarter of 2024.A...
Top-line data expected in December 2024 after having completed enrollment for Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA...
ANAB stock results show that AnaptysBio missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AnaptysBio (NASDAQ:ANAB) just reported results for the first quarter of 2024.An...
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by...
All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomized to monthly subcutaneous...
/PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive...
Wall Street stock predictions can run wild but after the tech sector's gains, these stocks could be better places for your money.
A powerfully bullish new analyst take on the company helped it rally on the market.
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist, with top-line data anticipated by year-end...
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...